Armata Pharmaceuticals, Inc. (ARMP) stock
ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.87+0.15 (+4.03%)
Close on Nov 13, 2026Market cap $143.89MP/E –Yield –
Armata Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Armata Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $26.60M, up 1.9% year over year. For fiscal 2025 it was $23.72M, down 31.1% from the year before. Over ten years it grew 19.5% a year on average. The highest annual figure on record is $35.02M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.72M | -31.1% |
| FY2024 | Dec 31, 2024 | $34.43M | +1.9% |
| FY2023 | Dec 31, 2023 | $33.77M | -3.6% |
| FY2022 | Dec 31, 2022 | $35.02M | +75.0% |
| FY2021 | Dec 31, 2021 | $20.02M | +38.6% |
| FY2020 | Dec 31, 2020 | $14.44M | +47.0% |
| FY2019 | Dec 31, 2019 | $9.82M | +17.3% |
| FY2018 | Dec 31, 2018 | $8.37M | +190.6% |
| FY2017 | Dec 31, 2017 | $2.88M | -49.3% |
| FY2016 | Dec 31, 2016 | $5.68M | +42.2% |
| FY2015 | Dec 31, 2015 | $3.99M | -31.2% |
| FY2014 | Dec 31, 2014 | $5.81M | -10.3% |
| FY2013 | Dec 31, 2013 | $6.47M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $6.83M | +17.3% |
| Q2 FY2026 | Jun 30, 2026 | $7.59M | +18.6% |
| Q1 FY2026 | Mar 31, 2026 | $6.11M | +12.6% |
| Q4 FY2025 | Dec 31, 2025 | $6.07M | -28.2% |
| Q3 FY2025 | Sep 30, 2025 | $5.82M | -38.6% |
| Q2 FY2025 | Jun 30, 2025 | $6.39M | -24.6% |
| Q1 FY2025 | Mar 31, 2025 | $5.43M | -32.3% |
| Q4 FY2024 | Dec 31, 2024 | $8.45M | +6.6% |
| Q3 FY2024 | Sep 30, 2024 | $9.49M | +18.9% |
| Q2 FY2024 | Jun 30, 2024 | $8.48M | +2.6% |
| Q1 FY2024 | Mar 31, 2024 | $8.02M | -16.5% |
| Q4 FY2023 | Dec 31, 2023 | $7.93M | -17.1% |
| Q3 FY2023 | Sep 30, 2023 | $7.98M | -5.0% |
| Q2 FY2023 | Jun 30, 2023 | $8.26M | -8.4% |
| Q1 FY2023 | Mar 31, 2023 | $9.60M | +19.6% |
| Q4 FY2022 | Dec 31, 2022 | $9.57M | +98.8% |
| Q3 FY2022 | Sep 30, 2022 | $8.40M | +49.3% |
| Q2 FY2022 | Jun 30, 2022 | $9.02M | +72.6% |
| Q1 FY2022 | Mar 31, 2022 | $8.03M | +84.6% |
| Q4 FY2021 | Dec 31, 2021 | $4.81M | -3.3% |
| Q3 FY2021 | Sep 30, 2021 | $5.63M | +38.4% |
| Q2 FY2021 | Jun 30, 2021 | $5.23M | +97.3% |
| Q1 FY2021 | Mar 31, 2021 | $4.35M | +58.2% |
| Q4 FY2020 | Dec 31, 2020 | $4.98M | +198.6% |
| Q3 FY2020 | Sep 30, 2020 | $4.07M | +34.7% |
| Q2 FY2020 | Jun 30, 2020 | $2.65M | -13.9% |
| Q1 FY2020 | Mar 31, 2020 | $2.75M | +33.4% |
| Q4 FY2019 | Dec 31, 2019 | $1.67M | -15.9% |
| Q3 FY2019 | Sep 30, 2019 | $3.02M | +57.7% |
| Q2 FY2019 | Jun 30, 2019 | $3.08M | +34.6% |
| Q1 FY2019 | Mar 31, 2019 | $2.06M | +40.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.98M | +82.0% |
| Q3 FY2018 | Sep 30, 2018 | $1.92M | +69.5% |
| Q2 FY2018 | Jun 30, 2018 | $2.29M | +53.4% |
| Q1 FY2018 | Mar 31, 2018 | $1.46M | +82.5% |
| Q4 FY2017 | Dec 31, 2017 | $1.09M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.13M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $802.00K | – |
See a number that looks wrong?